CAJ | 학술논문

目的：比较分析腔内等离子汽化切割系统行治疗良性前列腺增生（Benign prostatic hyperplasia, BPH）的两种术式：经尿道等离子前列腺电切术（Transurethral plasmakinetic resction of prostate,TUPKP）与经尿道等离子汽化剜切术（Tansurethral vpor Enucleation rsection of the prostate ,TVERP）的临床疗效。方法回顾性分析2009年10月至2014年11月在某院行 TUPKP 和 TVERP 治疗的良性前列腺增生的病例资料，其中 TUPKP 组70例，TVERP 组46例。通过手术操作用时、术中失血量、切除腺体体积、术后膀胱持续冲洗时间和并发症机率评价两种手术方式围手术期安全性；通过比较术后3个月前列腺症状主观及客观评分表、尿流动力学指标评价两种手术方式的疗效。结果两组数据比较 TVERP 治疗组术中出血量、术后膀胱冲洗时间相对低、前列腺切除重量相对高、并发症机率低（P＜0.05）；术后3个月两组最大尿流率（Qmax）、残尿量（PRV）、国际前列腺症状评分（IPSS）、生活质量评分（QOL）较术前均明显改善，但两组间比较差异无显著性（P＞0.05）。结论经尿道等离子汽化剜切术治疗前列腺增生手术安全性更好，短期疗效与等离子前列腺电切术相当,是一种治疗良性前列腺增生相对理想的手术方法。
목적：비교분석강내등리자기화절할계통행치료량성전렬선증생（Benign prostatic hyperplasia, BPH）적량충술식：경뇨도등리자전렬선전절술（Transurethral plasmakinetic resction of prostate,TUPKP）여경뇨도등리자기화완절술（Tansurethral vpor Enucleation rsection of the prostate ,TVERP）적림상료효。방법회고성분석2009년10월지2014년11월재모원행 TUPKP 화 TVERP 치료적량성전렬선증생적병례자료，기중 TUPKP 조70례，TVERP 조46례。통과수술조작용시、술중실혈량、절제선체체적、술후방광지속충세시간화병발증궤솔평개량충수술방식위수술기안전성；통과비교술후3개월전렬선증상주관급객관평분표、뇨류동역학지표평개량충수술방식적료효。결과량조수거비교 TVERP 치료조술중출혈량、술후방광충세시간상대저、전렬선절제중량상대고、병발증궤솔저（P＜0.05）；술후3개월량조최대뇨류솔（Qmax）、잔뇨량（PRV）、국제전렬선증상평분（IPSS）、생활질량평분（QOL）교술전균명현개선，단량조간비교차이무현저성（P＞0.05）。결론경뇨도등리자기화완절술치료전렬선증생수술안전성경호，단기료효여등리자전렬선전절술상당,시일충치료량성전렬선증생상대이상적수술방법。
Objective To report the comparison of the clinical effects for benign prostatic hyperplasia between transurethral plasmakinetic resction of prostate and transurethral vapor enucleation resection of the prostate.Methods A total of 116 patients with BPH were enrolled from October 2009 to Novermber 2014 and divided into TVERP group (46 cases) and TUPKP group(70cases).Parameters including intraoperative blood loss, resected tissue weight, operating time, postoperative washing time of bladder and postoperative morbidity rate were compared to evaluate the clinical safety of TVERP and TUPKP for the treatment of BPH.Results TVERP has lower intraoperative blood loss, complication and postoperative washing time of bladder, and has higher resected tissue weight(P<0.05). International prostate symptom scores(IPSS),quality of life scores(QOL),maximum urinary flow rates(Qmax) and postvoid residual volumes(PRV)of postoperation were significantly improved compared to 3 months preoperative. But there was no significant difference between two groups(P>0.05).Conclusion TVERP has higher security in the treatment of BPH.Both of them have similar efficacy in the treatment of BPH.TVERP is a relatively ideal treatment of benign prostatic hyperplasia.